Nucleus accumbens and dopamine-mediated turning behavior of the rat: Role of accumbal non-dopaminergic receptors

Journal of Pharmacological Sciences

Volumn 120, Issue 3, 2012, Pages 152-164

  Ikeda, Hiroko ^a,b   Kamei, Junzo ^b   Koshikawa, Noriaki ^a   Cools, Alexander R ^c  

^a NIHON UNIVERSITY   (Japan)

^b HOSHI UNIVERSITY   (Japan)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dopamine; Nucleus accumbens; Turning behavior

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; ACETYLCHOLINE; ALPHA ADRENERGIC RECEPTOR; AMPA RECEPTOR; BETA ADRENERGIC RECEPTOR; DELTA OPIATE RECEPTOR; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; MU OPIATE RECEPTOR; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR; NORADRENALIN; OREXIN; OREXIN 2 RECEPTOR; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN 2C RECEPTOR; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ACETYLCHOLINE RELEASE; CHOLINERGIC SYSTEM; CIRCLING BEHAVIOR; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; LOCOMOTION; MOTOR CONTROL; NERVE PROJECTION; NEUROMODULATION; NONHUMAN; NUCLEUS ACCUMBENS; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PIVOTING BEHAVIOR; RAT; REVIEW; SEROTONINERGIC SYSTEM; SUBSTANTIA NIGRA PARS COMPACTA; TURNING SYNDROME; VENTRAL TEGMENTUM;

EID: 84869437361     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12R02CR     Document Type: Review

References (100)

1. Kienast T, Heinz A. Dopamine and the diseased brain. CNS Neurol Disord Drug Targets. 2006;5:109-131. (Pubitemid 43796630)
2. Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiat. 2006;59:1151-1159. (Pubitemid 44192421)
3. Di Chiara G, Bassareo V, Fenu S, de Luca MA, Spina L, Cadoni C, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology. 2004;47 Suppl 1:227-241. (Pubitemid 39298267)
4. Heimer L. A new anatomical framework for neuropsychiatric disorders and drug abuse. Am J Psychiat. 2003;160:1726-1739. (Pubitemid 41103306)
5. Yamada K, Nagai T, Nabeshima T. Drug dependence, synaptic plasticity, and tissue plasminogen activator. J Pharmacol Sci. 2005;97:157-161. (Pubitemid 40410252)
6. Levy F. Synaptic gating and ADHD: a biological theory of comorbidity of ADHD and anxiety. Neuropsychopharmacology. 2004;29:1589-1596. (Pubitemid 39150100)
7. Sounga-Barke EJS. Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiat. 2005;57:1231-1238.
8. Grace AA. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Rev. 2000;31:330-341. (Pubitemid 30136188)
9. Pani L. Clinical implications of dopamine research in schizophrenia. Curr Med Res Opin. 2002;18 Suppl 3:s3-s7.
10. Olanow CW, Obeso JA, Stocchi F. Contnuous dopamine-receptor treatment of Parkinson's disease: rationale and clinical implications. Lancet Neurol. 2006;5:677-687. (Pubitemid 44081890)
11. Bardo MT, Hammer RP Jr. Autoradiographic localization of dopamine D1 and D2 receptors in rat nucleus accumbens: resistance to differential conditions. Neuroscience. 1991;45:281-290.
12. Deutch AY, Cameron DS. Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience. 1992;46:49-56.
13. Voorn P, Jorritsma-Byham B, van Dijk C, Buijs RM. The dopaminergic innervation of the ventral striatum in the rat: a light- and electron-microscopical study with antibodies against dopamine. J Comp Neurol. 1986;251:84-99. (Pubitemid 16012190)
14. Zahm DS, Heimer L. Specificity in the efferent projections of the nucleus accumbens in the rat: comparison of the rostral pole projection patterns with those of core and shell. J Comp Neurol. 1993;327:220-232. (Pubitemid 23019812)
15. Kitamura M, Koshikawa N, Yoneshige N, Cools AR. Behavioural and neurochemical effects of cholinergic and dopaminergic agonists administered into the accumbal core and shell in rats. Neuro pharmacology. 1999;38:1397-1407. (Pubitemid 29333156)
16. 1 receptors in the nucleus accumbens of rats is due to stimulation of these receptors in the shell, but not the core, of this nucleus. Psychopharmacology. 1996;126:185-190.
17. Koshikawa N. Role of the nucleus accumbens and the striatum in the production of turning behaviour in intact rats. Rev Neurosci. 1994;5:331-346.
18. A receptors in the pedunculopontine tegmental nucleus play a crucial role in rat shell-specific dopamine-mediated, but not shell-specific acetylcholine-mediated, turning behaviour. Neuroscience. 2004;125:553-562.
19. B receptors in two distinct output stations of the rat striatum: studies on the substantia nigra pars reticulata and the globus pallidus. Neuroscience. 2010;167:31-39.
20. Areceptors in the mediodorsal thalamus play a crucial role in rat shell-specific acetylcholine-mediated, but not dopamine-mediated, turning behavior. Neuroscience. 2009;159:1200-1207.
21. A agents injected into the ventral pallidum differentially affect dopaminergic pivoting and cholinergic circling elicited from the shell of the nucleus accumbens. Neuroscience. 2001;104:117-127.
22. Maggio R, Aloisi G, Silvano E, Rossi M, Millan MJ. Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance. Parkinsonism Relat Disord. 2009;15 Suppl 4:S2-S7.
23. Missale C, Fiorentini C, Collo G, Spano P. The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexes. J Recept Signal Transduct Res. 2010;30:347-354.
24. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol. 2005;67:1697-1704. (Pubitemid 40594170)
25. Kelly AE, Domesick VB. The distribution of projection from the hippocampal formation to the nucleus accumbens in the rat: an anterograde and retrograde horseradish peroxidase study. Neuroscience. 1982;7:2321-2335. (Pubitemid 12004419)
26. Robinson TG, Beart PM. Excitant amino acid projections from rat amygdala and thalamus to the nucleus accumbens. Brain Res Bull. 1988;20:467-471. (Pubitemid 19266440)
27. Walaas I. Biochemical evidence for overlapping neocortical and allocortical glutamate projections to the nucleus accumbens and rostral caudatoputamen in the rat brain. Neuroscience. 1981;6:399-405. (Pubitemid 11152468)
28. Sesack SR, Pickel VM. In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Res. 1990;527:266-279. (Pubitemid 20290606)
29. Sesack SR, Pickel VM. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neurol. 1992;320:145-160.
30. Young AB, Fagg GE. Excitatory amino acid receptors in the brain: membrane binding and receptor autoradiographic approaches. 1990;11:126-133.
31. Imperato A, Honoré T, Jensen LH. Dopamine release in the nucleus caudatus and in the nucleus accumbens is under glutamatergic control through non-NMDA receptors: a study in free-moving rats. Brain Res. 1990;530:223-228. (Pubitemid 20340698)
32. Dalia A, Uretsky NJ, Wallace LJ. Dopaminergic agonists administered into the nucleus accumbens: Effects on extracellular glutamate and on locomotor activity. Brain Res. 1998;788:111-117. (Pubitemid 28202150)
33. Boldry RC, Uretsky NJ. The importance of dopaminergic neurotransmission in the hypermotility response produced by the administration of N-methyl-D-aspartic acid into the nucleus accumbens. Neuropharmacology. 1988;27:569-577.
34. Boldry RC, Willins DL, Wallace LJ, Uretsky NJ. The role of endogenous dopamine in the hypermotility response to intra-accumbens AMPA. Brain Res. 1991;559:100-108.
35. Ikeda H, Akiyama G, Fujii Y, Minowa R, Koshikawa N, Cools AR. Role of AMPA and NMDA receptors in the nucleus accumbens shell in turning behavior of rats: interaction with dopamine receptors. Neuropharmacology. 2003;44:81-87. (Pubitemid 36135844)
36. Taber MT, Baker GB, Fibiger HC. Glutamate receptor agonists decrease extracellular dopamine in the rat nucleus accumbens in vivo. Synapse. 1996;24:165-172. (Pubitemid 26339309)
37. Kaddis FG, Wallace LJ, Uretsky NJ. AMPA/kainate antagonists in the nucleus accumbens inhibit locomotor stimulatory response to cocaine and dopamine agonists. Pharmacol Biochem Behav. 1993;46:703-708.
38. Pulvirenti L, Swerdlow NR, Koob GF. Nucleus accumbens NMDA antagonist decreases locomotor activity induced by cocaine, heroin or accumbens dopamine, but not caffeine. Pharmacol Biochem Behav. 1991;40:841-845.
39. Hara Y, Pickel VM. Overlapping intracellular and differential synaptic distributions of dopamine D1 and glutamate N-methyl-D-aspartate receptors in rat nucleus accumbens. J Comp Neurol. 2005;492:442-455. (Pubitemid 41572461)
40. Carr KD, Chau LS, de Vaca C, Gustafson K, Stouffer M, Tukey DS, et al. AMPA receptor subunit GluR1 downstream of D-1 dopamine receptor stimulation in nucleus accumbens shell mediates increased drug reward magnitude in food-restricted rats. Neuroscience. 2010;165:1074-1086.
41. Matsumoto RR. GABA receptors: are cellular differences reflected in function? Brain Res Rev. 1989;14:203-225. (Pubitemid 19247335)
42. Rahman S, McBride WJ. Involvement of GABA and cholinergic receptors in the nucleus accumbens on feedback control of somatodendritic dopamine release in the ventral tegmental area. J Neurochem. 2002;80:646-654. (Pubitemid 34809973)
43. Pycock CJ, Horton RW. Dopamine-dependent hyperactivity in the rat following manipulation of GABA mechanisms in the region of the nucleus accumbens. J Neural Trans. 1979;45:17-33. (Pubitemid 9174612)
44. Scheel-Krüger J, Cools AR, Van Wel PM. Muscimol a GABA-agonist injected into the nucleus accumbens increases apomorphine stereotypy and decreases the motility. Life Sci. 1977;21:1697-1702. (Pubitemid 9038731)
45. Wong LS, Eshel G, Dreher J, Org J, Jackson DM. Role of dopamine and GABA in the control of motor activity elicited from the rat nucleus accumbnes. Pharmacol Biochem Behav. 1991;38:829-835.
46. B receptors in the nucleus accumbens shell differentially modulate dopamine and acetylcholine receptor-mediated turning behaviour. Neuropharmacology. 2004;46:1082-1088.
47. 3 receptors regulate GABAA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens. J Neurosci. 2006;26:2513-2521.
48. 1receptor stimulation in shell and core of the nucleus accumbens. Neuroscience. 1999;89:1209-1217.
49. 2 dopamine receptor mediation of amphetamine-induced acetylcholine release in nucleus accumbens. Neuroscience. 1998;86:521-531.
50. Ichikawa J, Chung YC, Li Z, Dai J, Meltzer HY. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res. 2002;958:176-184. (Pubitemid 35441226)
51. Threlfell S, Clements MA, Khodai T, Pienaar IS, Exley R, Wess J. Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum. J Neurosci. 2010;30:3398-3408.
52. Fu Y, Matta G, Gao W, Sharp BM. Local α-bungarotoxinsensitive nicotinic receptors in the nucleus accumbens modulate nicotine-stimulated dopamine secretion in vivo. Neuroscience. 2000;101:369-375.
53. de Rover M, Lodder JC, Kits KS, Schoffelmeer ANM, Brussaard AB. Cholinergic modulation of nucleus accumbens medium spiny neurones. Eur J Neurosci. 2002;16:2279-2290. (Pubitemid 36056952)
54. Quarta D, Ciruela F, Patkar K, Borycz J, Solinas M, Lluis C, et al. Heteromeric nicotinic acetylcholine-dopamine autoreceptor complexes modulate striatal dopamine release. Neuropsychopharmacology. 2007;32:35-42. (Pubitemid 44967782)
55. Moribe S, Ikeda H, Sato M, Akiyama G, Matsuzaki S, Hasegawa K, et al. Acetylcholine receptor effects on accumbal shell dopamine- mediated turning behvaviour in rats. Neuropharmacology. 2005;49:514-524. (Pubitemid 41169975)
56. Onali P, Olianas MC. Muscarinic M4 receptors inhibition of dopamine D1-like receptor signalling in rat nucleus accumbens. Eur J Pharmacol. 2002;448:105-111. (Pubitemid 34874575)
57. Delfs JM, Zhu Y, Druhan JP, Aston-Jones GS. Origin of noradrenergic afferents to the shell subregion of the nucleus accumbens: anterograde and retrograde tract-tracing studies in the rat. Brain Res. 1998;806:127-140. (Pubitemid 29010488)
58. Cools AR, van den Bos R, Ploeger G, Ellenbroek BA. Gating function of noradrenaline in the ventral striatum: its role in behavioural responses to environmental and pharmacological challenges. In: Willner P, Scheel-Krüger J, editors. The mesolimbic dopamine system: from motivation to action. Chichester: John Wiley & Sons Ltd.; 1991. p. 141-173.
59. Verheij MM, Cools AR. Twenty years of dopamine research: individual differences in the response of accumbal dopamine to environmental and pharmacological challenges. Eur J Pharmacol. 2008;585:228-244.
60. Verheij MM, Cools AR. Accumbal noradrenaline that contributes to the alpha-adrenoceptor-mediated release of dopamine from reserpine-sensitive storage vesicles in the nucleus accumbens is derived from alpha-methyl-para-tyrosine- sensitive pools. J Neural Transm. 2009;116:389-394.
61. Verheij MM, Cools AR. Mesolimbic alpha-, but not beta-adrenoceptors control the accumbal release of dopamine that is derived from reserpine-sensitive storage vesicles. Neuroscience. 2009;162:1163-1173.
62. Ikeda H, Moribe S, Sato M, Kotani A, Koshikawa N, Cools AR. Adrenergic receptors in the nucleus accumbens shell differentially modulate dopamine and acetylcholine receptor-mediated turning behaviour. Eur J Pharmacol. 2007;554:175-182. (Pubitemid 44883310)
63. White FJ, Bednarz LM, Wachtel SR, Hjorth S, Brooderson RJ. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors? Pharmacol Biochem Behav. 1988;30:189-193. (Pubitemid 19268808)
64. Barns NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38:1083-1152. (Pubitemid 29292403)
65. Moore RY, Halaris AE, Jones BE. Serotonin neurons in the midbrain raphe: ascending projections. J Comp Neurol. 1978;180:417-438.
66. Guan XM, McBride WJ. Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull. 1989;23:541-547. (Pubitemid 20035318)
67. 1B/1D receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: a microdialysis study. Eur J Pharmacol. 2001;418:55-64.
68. 2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in rats. Psychopharmacology. 2011;213:321-335.
69. 2C receptors in nucleus accumbens regulate expression of the hyperlocomotive and discriminative stimulus effects of cocaine. Pharmacol Biochem Behav. 2002;71:745-756.
70. 1Breceptor ligands microinjected into the accumbal shell or core on the cocaine-induced locomotor hyperactivity in rats. J Physiol Pharmacol. 2002;53:383-394.
71. Spanagel R, Herz A, Shippenberg TS. The effects of opioid peptide on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem. 1990;55:1734-1740.
72. Yoshida Y, Koide S, Hirose N, Takada K, Tomiyama K, Koshikawa N, et al. Fentanyl increases dopamine release in rat nucleus accumbens: involvement of mesolimbic mu- and delta-2-opioid receptors. Neuroscience. 1999;92:1357-1365. (Pubitemid 29292571)
73. 1-dependent stereotypies and stimulation of dopamine release in the nucleus accumbens. J Neurosci. 1991;11:1565-1576.
74. Spanagel R, Herz A, Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A. 1992;89:2045-2050.
75. Kalivas PW, Widerlöv E, Stanley D, Breese G, Prange AJ Jr. Enkephalin action on the mesolimbic system: a dopamine-dependent and dopamine-independent increase in locomotor activity. J Pharmacol Exp Ther. 1983;227:229-237. (Pubitemid 14205294)
76. Stinus L, Koob GF, Ling N, Bloom FE, Moal ML. Locomotor activation induced by infusion of endorphins into the ventral tegmental area: evidence for opiate-dopamine interactions. Proc Natl Acad Sci U S A. 1980;77:2323-2327. (Pubitemid 10093456)
77. Churchill L, Kalivas PW. Dopamine depletion produces augmented behavioral responses to a mu-, but not a delta-opioid receptor agonist in the nucleus accumbens: lack of a role for receptor upregulation. Synapse. 1992;11:47-57.
78. Matsuzaki S, Ikeda H, Akiyama G, Sato M, Moribe S, Suzuki T, et al. Role of μ- and δ-opioid receptors in the nucleus accumbens in turning behavior of rats. Neuropharmacology. 2004;46:1089-1096. (Pubitemid 38529932)
79. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573-585. (Pubitemid 28101119)
80. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleeping and wakefulness. Nat Rev Neurosci. 2007;8:171-181. (Pubitemid 46294664)
81. Samson WK, Gosnell B, Chang J-K, Resch ZT, Murphy TC. Cardiovascular regulatory actions of the hypocretins in brain. Brain Res. 1999;831:248-253. (Pubitemid 29336207)
82. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996-10015. (Pubitemid 28543775)
83. Trivedi P, Yu H, MacNeil DJ, Van der Plog LHT, Guan X-M. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett. 1998;438:71-75. (Pubitemid 28517837)
84. Fadel J, Deutch Y. Anatomical substrates of orexin-dopamine interactions: lateral hypothalamus projections to the ventral tegmental area. Neuroscience. 2002;111:379-387. (Pubitemid 34442621)
85. Nakamura T, Uramura K, Nambu T, Yada T, Goto K, Yanagisawa M, et al. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res. 2000;873:181-187. (Pubitemid 30468504)
86. Narita M, Nagumo Y, Hashimoto S, Narita M, Khotib J, Miyatake M, et al. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci. 2006;26:398-405. (Pubitemid 43237102)
87. Kotani A, Ikeda H, Koshikawa N, Cools AR. Role of orexin receptors in the nucleus acumbens in dopamine-dependent turning behavior of rats. Neuropharmacology. 2008;54:613-619.
88. Mori K, Kim J, Sasaki K. Electrophysiological effects of orexin-B and dopamine on rat nucleus accumbens shell neurons in vitro. Peptides. 2011;32:246-252.
89. Brazeau P, Vale W, Burgus R, Ling M, Butcher J, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179:77-79.
90. Brownstein M, Arimura A, Sato H, Schally AV, Kizer JS. The regional distribution of somatostatin in the rat brain. Endocrinology. 1975;96:1456-1461.
91. Martin JL, Chesselet M-F, Raynor K, Gonzales C, Reisine T. Differential distribution of somatostatin receptor subtypes in rat brain revealed by newly developed somatostatin analogs. Neuroscience. 1991;41:581-593.
92. Beal MF, Domesick VB, Martin JB. Regional somatostatin distribution in the rat striatum. Brain Res. 1983;278:103-108. (Pubitemid 14219278)
93. Hathway GJ, Emson PC, Humphrey PPA, Kendrick KM. Somatostatin potently stimulate in vivo striatal dopamine and γ-aminobutyric acid release by a glutamate-dependent action. J Neurochem. 1998;70:1740-1749. (Pubitemid 28136991)
94. Beal MF, Martin JB. Effects of neuroleptic drugs on brain somatostatin-like-immunoreactivity. Neurosci Lett. 1984;47:125-130. (Pubitemid 14123269)
95. 2-receptor agonist and antagonist drugs on somatostatin binding, inhibition of adenylyl cyclase activity and accumulation of inositol 1,4,5-trisphosphate in the rat striatum. Mol Brain Res. 1997;47:99-107.
96. Lee N, Radke M, Vincent SR. Intra-cerebral cysteamine infusions attenuate the motor response to dopaminergic agonists. Behav Brain Res. 1988;29:179-183.
97. Pallis E, Thermos K, Spyraki C. Chronic desipramine treatment selectively potentiates somatostatin-induced dopamine release in the nucleus accumbens. Eur J Neurosci. 2001;14:763-767. (Pubitemid 34626003)
98. Ikeda H, Kotani A, Koshikawa N, Cools AR. Somatostatin receptors in the nucleus accumbens modulate dopamine-dependent but not acetylcholine-dependent turning behavior of rats. Neuroscience. 2009;159:974-981.
99. Lopez-Huerta VG, Tecuapetla F, Guzman JN, Bargas J, Galarraga E. Presynaptic modulation of somatostatin in the neostriatum. Neurochem Res. 2008;33:1452-1458.
100. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000;288:154-157. (Pubitemid 30203051)